Ceacam1-targeting antibodies and uses thereof
AssigneeSuzhou Neologics Bioscience Co., Ltd.
InventorsXin Dong, Yu Zhang, Jinyu Dong, Binbin Wang, Dong Wang, Tingting Bu
Life of this patent
Estimating the term…
Abstract
Provided are anti-CEACAM1 antibodies and antigen-binding fragments, polynucleotides encoding the antibodies and antigen-binding fragments, and pharmaceutical compositions comprising the antibodies and antigen-binding fragments. Also provided are uses of the anti-CEACAM1 antibodies and antigen-binding fragments described herein in, for example, cancer treatment.
Claims64
An antibody or antigen-binding fragment thereof that specifically binds to human CEACAM1, comprising:
- (a) a light chain variable region (VL) comprising
- (1) a light chain CDR1 (VL CDR1) having an amino acid sequence selected from the group consisting of SEQ ID NOs:1-7 and 52-53;
- (2) a light chain CDR2 (VL CDR2) having an amino acid sequence selected from the group consisting of SEQ ID NOs:8-12 and 54-56;
- and
- (3) a light chain CDR3 (VL CDR3) having an amino acid sequence selected from the group consisting of SEQ ID NOs:13-19;
- or a variant thereof having up to about 3 amino acid substitutions, additions, and/or deletions in the VL CDRs;
- and/or
- (b) a heavy chain variable region (VH) comprising
- (1) a heavy chain CDR1 (VH CDR1) having an amino acid sequence selected from the group consisting of SEQ ID NOs:20-27 and 57;
- (2) a heavy chain CDR2 (VH CDR2) having an amino acid sequence selected from the group consisting of SEQ ID NOs:28-39;
- and
- (3) a heavy chain CDR3 (VH CDR3) having an amino acid sequence selected from the group consisting of SEQ ID NOs:40-51;
- or a variant thereof having up to about 3 amino acid substitutions, additions, and/or deletions in the VH CDRs.
An antibody or antigen-binding fragment thereof that specifically binds to human CEACAM1, comprising:
- (a) a VL having at least 85%, at least 90%, at least 95%, at least 98%, or 100% sequence identity to an amino acid sequence selected from the group consisting of SEQ ID NOs:61-68;
- and/or
- (b) a VH having at least 85%, at least 90%, at least 95%, at least 98%, or 100% sequence identity to an amino acid sequence selected from the group consisting of SEQ ID NOs:70-78.
An antibody or antigen-binding fragment thereof that specifically binds to human CEACAM1, comprising:
- (a) a VL comprising VL CDR1, CDR2, and CDR3 from a VL having an amino acid sequence selected from the group consisting of SEQ ID NOs:61-68;
- and/or
- (b) a VH comprising VH CDR1, CDR2, and CDR3 from a VH having an amino acid sequence selected from the group consisting of SEQ ID NOs:70-78;
- or a variant thereof having up to about 3 amino acid substitutions, additions, and/or deletions in the CDRs.
An antibody or antigen-binding fragment thereof that specifically binds to human CEACAM1 comprising a VL and a VH, wherein the VL comprises VL CDR1, CDR2, and CDR3 from a VL having the amino acid sequence of SEQ ID NO:63, and the VH comprises VH CDR1, CDR2, and CDR3 from a VH having the amino acid sequence of SEQ ID NO:72;
- or a variant thereof having up to about 3 amino acid substitutions, additions, and/or deletions in the CDRs.
An antibody or antigen-binding fragment thereof that specifically binds to human CEACAM1 comprising a VL and a VH, wherein the VL comprises VL CDR1, CDR2, and CDR3 from a VL having the amino acid sequence of SEQ ID NO:65, and the VH comprises VH CDR1, CDR2, and CDR3 from a VH having the amino acid sequence of SEQ ID NO:74;
- or a variant thereof having up to about 3 amino acid substitutions, additions, and/or deletions in the CDRs.
An antibody or antigen-binding fragment thereof that specifically binds to human CEACAM1 comprising a VL and a VH, wherein the VL comprises VL CDR1, CDR2, and CDR3 from a VL having the amino acid sequence of SEQ ID NO:66, and the VH comprises VH CDR1, CDR2, and CDR3 from a VH having the amino acid sequence of SEQ ID NO:75;
- or a variant thereof having up to about 3 amino acid substitutions, additions, and/or deletions in the CDRs.
Dependencies are inferred from the claim text.